Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

The ABC-14 regimen (Azacitidine, Venetoclax, and Chidamide) as a bridge to allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia: A single-center experience

View Full Paper
Ask AI
Bookmark
Share

Authors

XCXiaomei ChenLHLisi HuangMLMinming Li

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals ABC-14 regimen maintains engraftment and reduces relapse in patients undergoing transplant for acute myeloid leukemia, suggesting efficacy over intensive chemotherapy.

Key Points

  • The ABC-14 regimen led to comparable post-transplant outcomes in patients with acute myeloid leukemia.
  • Engraftment was achieved in all patients, with no significant differences in times to neutrophil and platelet recovery.
  • Patients receiving ABC-14 experienced no relapses during follow-up, while relapse occurred in the intensive chemotherapy cohort.
  • This study supports further evaluation of the ABC-14 regimen as a feasible bridging strategy for AML patients.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236dbb5https://doi.org/10.1182/blood-2025-5991
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparing the efficacy and safety of the ABC-14 regimen (Azacitidine, Venetoclax, and Chidamide) with traditional “3+7” intensive induction regimen or AB-14 regimen (Venetoclax Combined with Azacitidine) in newly diagnosed AML: Study protocol for a prospective, multicenter, randomized, open-label clinical trial2025
  2. 2Intensive chemotherapy bridging to allogeneic hematopoietic cell transplant in relapsed or refractory Acute Myeloid Leukemia2025
  3. 3The efficacy and safety of venetoclax-based and anthracycline-free induction therapy followed by allogeneic hematopoietic stem cell transplantation in the treatment of transplant-eligible Acute Myeloid Leukemia patients2025
  4. 4Efficacy and safety of azacitidine, venetoclax combined with gha priming regimen in the treatment of adult refractory and relapsed acute myeloid leukemia: A prospective single-arm multicenter study2025
  5. 5Cladribine, cytarabine, and venetoclax-based regimens are associated with durable remissions in patients (pts) with newly diagnosed Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation2025